A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer

SIMPLE SUMMARY: Through analysis of specimens from patients with primary triple-negative breast cancer (TNBC) enrolled in a neoadjuvant clinical trial assessing durvalumab with chemotherapy, we confirmed a novel 27-gene immuno-oncology (IO) signature that generates an IO score to predict the patholo...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwase, Toshiaki, Blenman, Kim R. M., Li, Xiaotong, Reisenbichler, Emily, Seitz, Robert, Hout, David, Nielsen, Tyler J., Schweitzer, Brock L., Bailey, Daniel B., Shen, Yichao, Zhang, Xiang, Pusztai, Lajos, Ueno, Naoto T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508147/
https://www.ncbi.nlm.nih.gov/pubmed/34638323
http://dx.doi.org/10.3390/cancers13194839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508147/
https://www.ncbi.nlm.nih.gov/pubmed/34638323
http://dx.doi.org/10.3390/cancers13194839

Ejemplares similares